Research trends of neoadjuvant therapy in lung cancer: a bibliometric analysis
This is the first bibliometric study of neoadjuvant therapy in lung cancer. Over the past two decades, interest in this field has steadily increased, particularly since 2017. The United States is the largest contributor and has the highest number of publications in this field. Immune checkpoint inhibitors, clinical trials, efficacy, and NSCLC are hotspots in neoadjuvant therapy for lung cancer, both now and in the foreseeable future.
Authors
- Xiaoru Geng
- Buhai Wang (ORCID: https://orcid.org/0000-0001-6391-4502)
- Juan J. Gu (ORCID: https://orcid.org/0009-0003-4640-2152)
- Yao Lu (ORCID: https://orcid.org/0000-0001-6743-7870)
- Yichun Zeng
- Yichen Liang (ORCID: https://orcid.org/0009-0007-9382-7267)
- Wenmiao Cao (ORCID: https://orcid.org/0000-0002-9519-3823)
- Youqin Jiang
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Northern Jiangsu People's Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1007/s12672-025-02011-6
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00